实用临床医药杂志2012，Vol.16Issue(9)：21-24,4.
依据ERCC1及RRM1对晚期非小细胞肺癌实施个体化治疗的随机对照临床研究
Randomized and controlled clinical research of personalized therapy for advanced non- small cell lung cancer according to ERCC1 and RRM1
摘要
Abstract
Objective To select sensitive drugs according to the detection results of excision repair cross - complementation group 1 (ERCC1) and ribonucleotide reductase Ml (RRM1) in advanced non-small cancer lung cancer (NSCLC) patients and observe the effect differences so as to guide individual treatment. Methods Combined detection of ERCC1 and RRM1 of tumor cells was performed in advanced NSCLC patients diagnosed pathologically. The patients were divided into two groups with a proportion of 2:1. The control group received gemcitabine and cisplatin, while the gene group was divided into four subgroups according to ERCC1 and RRM1 and received indi vidual therapy separately. The short - term and long - term effects were observed. Results A total of 174 patients were observed, and the overall efficacy rate was 44.2%. The efficacy rate was 37. 5% in the control group and 47. 5% in the gene group. The difference was statistically iasignifi-cant. The efficacy rate of ERCC1( - ) (56.7%) was higher than that of ERCC1( + ) (37.9%)in gene group, and the difference was statistically significant. The median progression - free survival, median survival and 1 year survival rate in each group had no significant difference. Conclusion The use of individual therapy in patients with lower expressions of ERCC1 can obtain higher efficacy rate, while the patients with higher expressions of ERCC1 may have drug resistance to platinums.关键词
交叉互补基因1/核糖核苷酸还原酶M1/随机对照/非小细胞肺癌/化疗Key words
excision repair cross - complementation group 1 (ERCC1)/ribonucleotide reductase Ml (RRM1)/randomized and controlled/non-small cell lung cancer/chemotherapy分类
医药卫生引用本文复制引用
陈佳,王建红,杨书云,尹海兵,谭清和,何松,张晓东,郭燕,朱亚芳,吉志固,陆俊国,陶玉,朱兴华..依据ERCC1及RRM1对晚期非小细胞肺癌实施个体化治疗的随机对照临床研究[J].实用临床医药杂志,2012,16(9):21-24,4.基金项目
江苏省卫生厅面上项目(H200867) （H200867）
中国高校医学期刊临床专项资金(11220044) （11220044）
